Thomas et al. confirmed the combination of CpG with CTLA-4 or PD-1 blockade not only increased the levels of circulating tumor-specific CD8+ T cells, but also reduced the number of Tregs at the tumor site (Mangsbo et al., 2010). This evidence concerns the gene PDCD1 and neoplasm.